{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}],"title":"Tingling in Hands/Feet"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}],"title":"Worry"},{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}],"title":"Getting Around"}],"denomUnitsSelected":"Visits","denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"209"}],"units":"Visits"}],"description":"Sources of distress will be assessed using the NCCN DT Problem List by examining the percentage of visits where types of problems are reported. The problem list includes 39 possible problems from which patients can choose. The problems are reported as a number and % of the total number of visits where problem lists are reported.","groups":[{"description":"Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023","id":"OG000","title":"Multiple Myeloma/Blenrep Participants"}],"paramType":"COUNT_OF_UNITS","reportingStatus":"POSTED","timeFrame":"Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.","title":"Sources of Distress Using NCCN DT: Top 5 Most Frequently Reported Problems","type":"SECONDARY","typeUnitsAnalyzed":"Visits","unitOfMeasure":"Visits"}